Efficacy of programmed death 1 inhibitors (nivolumab or pembrolizumab) in non-melanoma subjects
Latest Information Update: 20 Jul 2016
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 20 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology